Plain-English translation of NCT07798778 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new treatment called , a radioactive medication designed to find and attack prostate cancer cells that have spread to other parts of the body. The medication works by targeting a specific protein found on cancer cells. Researchers want to learn whether this treatment is safe, how well it works against the cancer, and how your body processes it.
Men with advanced prostate cancer often run out of treatment options when their cancer stops responding to standard hormone therapies. This medication offers a potentially new approach by using targeted radiation to kill cancer cells, giving patients another tool when other treatments no longer work.
You likely qualify if…
You likely don't qualify if…
You will receive as an injection into your vein according to the study plan. The research team will carefully monitor your safety and health through blood tests, imaging scans, and follow-up visits to see how your body responds to the treatment and whether your cancer improves. The study is designed for a small group of 18 patients to gather initial safety and effectiveness information.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China